The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | The need for collaboration amongst hospitals: learning from RATIFY
The recent RATIFY study (NCT00651261), which led to the approval of midostaurin for the treatment of FLT3-mutated AML patients, was made possible through the cooperation of many hospitals sharing patient data. Speaking from the European School of Hematology (ESH) International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal, Miguel Sanz, MD, of the University Hospital La Fe, Valencia, Spain, discusses why this collaboration is so vital to identifying new subtypes of and treatments for diseases.
